Abstract
The pharmacokinetics of cefaclor and cephalexin were characterized in patients with creatinine clearances ranging from 0 to 147 ml/min. Each of 24 fasted subjects received a single 500-mg oral dose of cefaclor, and 13 of these subjects later received 500 mg of cephalexin. Serum and urine levels of the antibiotics were measured by bioassay. The serum half-lives were highly correlated with corrected creatinine clearance (cefaclor r = 0.92, cephalexin r = 0.94). Linear regression estimates of the half-life of cefaclor were 2.3 h in the anephric patient and 40 min in the patient with a corrected creatinine clearance of 100 ml/min. For cephalexin, corresponding half-lives were 15.4 h and 58 min. We present a dosage nomogram for calculating the appropriate adjustments to the loading dose based on patient weight and maintenence dose based on corrected creatinine clearance.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bloch R., Szwed J. J., Sloan R. S., Luft F. C. Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure. Antimicrob Agents Chemother. 1977 Dec;12(6):730–732. doi: 10.1128/aac.12.6.730. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brogard J. M., Pinget M., Dorner M., Lavillaureix J. Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function. J Clin Pharmacol. 1975 Oct;15(10):666–673. doi: 10.1002/j.1552-4604.1975.tb05918.x. [DOI] [PubMed] [Google Scholar]
- Gentamicin dosage. Ann Intern Med. 1977 Mar;86(3):357–359. doi: 10.7326/0003-4819-86-3-357. [DOI] [PubMed] [Google Scholar]
- Greene D. S., Flanagan D. R., Quintiliani R., Nightingale C. H. Pharmacokinetics of cephalexin: an evaluation of one- and two-compartment model pharmacokinetics. J Clin Pharmacol. 1976 May-Jun;16(5-6):257–264. doi: 10.1002/j.1552-4604.1976.tb02402.x. [DOI] [PubMed] [Google Scholar]
- Hull J. H., Sarubbi F. A., Jr Gentamicin serum concentrations: pharmacokinetic predictions. Ann Intern Med. 1976 Aug;85(2):183–189. doi: 10.7326/0003-4819-85-2-183. [DOI] [PubMed] [Google Scholar]
- Korzeniowski O. M., Scheld W. M., Sande M. A. Comparative pharmacology of cefaclor and cephalexin. Antimicrob Agents Chemother. 1977 Aug;12(2):157–162. doi: 10.1128/aac.12.2.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nightingale C. H., Greene D. S., Quintiliani R. Pharmacokinetics and clinical use of cephalosporin antibiotics. J Pharm Sci. 1975 Dec;64(12):1899–1926. doi: 10.1002/jps.2600641202. [DOI] [PubMed] [Google Scholar]
- Scheld W. M., Korzeniowski O. M., Sande M. A. In vitro susceptibility studies with cefaclor and cephalexin. Antimicrob Agents Chemother. 1977 Aug;12(2):290–292. doi: 10.1128/aac.12.2.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Spyker D. A., Rugloski R. J., Vann R. L., O'Brien W. M. Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration. Antimicrob Agents Chemother. 1977 Jan;11(1):132–141. doi: 10.1128/aac.11.1.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sullivan H. R., Due S. L., Kau D. L., Quay J. F., Miller W. Metabolism of (14C) cefaclor, a cephalosporin antibiotic, in three species of laboratory animals. Antimicrob Agents Chemother. 1976 Oct;10(4):630–638. doi: 10.1128/aac.10.4.630. [DOI] [PMC free article] [PubMed] [Google Scholar]